Obsidian Therapeutics

The company's core business revolves around its proprietary cytoDRiVE® platform, which functions as a pharmacologic operating system for cell therapies. This technology utilizes drug-responsive domains (DRDs) to precisely control the timing and level of protein function within the body. By using FDA-approved small-molecule drugs as an on/off switch, physicians can regulate the activity of engineered cells, enhancing their therapeutic effect while mitigating potential toxicity. This approach is designed to improve the safety and efficacy of powerful treatments like cytokine-based therapies.

Obsidian's primary market is oncology, specifically targeting solid tumors. Their clients are patients with intractable diseases, such as advanced or metastatic melanoma and non-small cell lung cancer (NSCLC). The company's business model is centered on the clinical development and potential commercialization of its therapeutic pipeline, funded through substantial venture capital financing. Obsidian has successfully raised hundreds of millions in funding from investors including GV (formerly Google Ventures), Wellington Management, and Bristol Myers Squibb.

The lead product candidate is OBX-115, an engineered tumor-infiltrating lymphocyte (TIL) therapy. This therapy arms a patient's own T cells with regulated membrane-bound IL15 (mbIL15), a cytokine that promotes the persistence and potency of the therapeutic cells. A key benefit of OBX-115 is that it is designed to eliminate the need for concomitant high-dose IL2 therapy, a treatment required for conventional TIL therapies that is associated with significant toxicity and cost. Clinical trial data has shown promising objective response rates in patients with advanced melanoma. The company is actively enrolling patients in a Phase 1/2 multicenter study for melanoma and NSCLC.